Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2003
09/12/2003WO2003011893A3 Immunologically significant herpes simplex virus antigens and methods for using same
09/12/2003WO2003007935A3 Use of a class of antiviral compounds for production of an agent for the treatment or prevention of a viral infection in the respiratory tract
09/12/2003WO2003002522A3 Peptide deformylase inhibitors
09/12/2003WO2002102325A3 Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c
09/12/2003WO2002098874A3 Inhalation capsules
09/12/2003WO2002060871A3 Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor
09/12/2003WO2002058732B1 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
09/12/2003WO2002058695A9 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
09/12/2003WO2002056884A3 Treatment of malaria with farnesyl protein transferase inhibitors
09/12/2003WO2002044420A3 Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
09/12/2003WO2002043717A3 Treatment of varicose veins
09/12/2003WO2002040486A3 METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS
09/12/2003WO2002032961A8 Novel polypeptides and nucleic acids encoding same
09/12/2003WO2002030447A3 Treatment of demyelinating diseases by administering gpe
09/12/2003WO2002028855A3 Amorphous form of cell cycle inhibitor
09/12/2003WO2002028424A9 Kyberdrug as autovaccines with immune-regulating effects
09/12/2003WO2002009726A9 Methods of treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds
09/12/2003WO2002009683A3 Aldosterone blocker therapy to prevent or treat inflammation-related disorders
09/12/2003WO2002005853A3 Compositions containing alpha-2-adrenergic agonist components
09/12/2003WO2002004443A3 Heterocycle carboxamides as antiviral agents
09/12/2003CA2841310A1 Electrolyte purgative
09/12/2003CA2706618A1 Quinoline derivatives
09/12/2003CA2481307A1 Phthalimide carboxylic acid derivatives
09/12/2003CA2478618A1 Isoquinoline derivatives
09/12/2003CA2478612A1 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
09/12/2003CA2478528A1 Semicarbazide derivatives and the use thereof as antithrombotics
09/12/2003CA2478520A1 Thiazole and oxazole derivatives which modulate ppar activity
09/12/2003CA2478425A1 Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release
09/12/2003CA2478424A1 Self emulsifying drug delivery systems for poorly soluble drugs
09/12/2003CA2478378A1 Novel use of cytokine inhibitors
09/12/2003CA2478164A1 Substituted thiazoles and oxazoles that modulate ppar activity
09/12/2003CA2478145A1 Formulations and methods of using nitric oxide mimetics in cancer treatment
09/12/2003CA2478135A1 Electrolyte purgative
09/12/2003CA2478133A1 Anti-infective agents and/or immunomodulators used for preventive therapy following an acute cerebrovascular accident
09/12/2003CA2478124A1 Dna demethylase antisense and chemotherapy combination
09/12/2003CA2478101A1 Intraorally rapidly disintegrable tablets
09/12/2003CA2478093A1 Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
09/12/2003CA2478050A1 Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
09/12/2003CA2478042A1 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
09/12/2003CA2477964A1 Liquid matrix transforming its phase in living body and oral liquid preparation
09/12/2003CA2477926A1 Crystalline polymorphic form of irinotecan hydrochloride
09/12/2003CA2477923A1 Multiple-component solid phases containing at least one active pharmaceutical ingredient
09/12/2003CA2477900A1 Composition for preventing hypertension
09/12/2003CA2477795A1 Nucleoside 5'-monophosphate mimics and their prodrugs
09/12/2003CA2477785A1 Isolation, purification and structural identification of a bioactive component of a water soluble extract of a botanical species for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
09/12/2003CA2477721A1 Bicyclic pyridine and pyrimidine p38 kinase inhibitors
09/12/2003CA2477717A1 Indolamid derivatives which possess glycogen phosphorylase inhibitory activity
09/12/2003CA2477667A1 Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase
09/12/2003CA2477662A1 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof
09/12/2003CA2477505A1 Diamino-pyrimidines and their use as angiogenesis inhibitors
09/12/2003CA2477449A1 Aminoalkylphosphonates and related compounds as edg receptor agonists
09/12/2003CA2477423A1 Aminoalkylphosphonates and related compounds as edg receptor agonists
09/12/2003CA2477422A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells
09/12/2003CA2477403A1 Use of epothilones in the treatment of brain diseases associated with proliferative processes
09/12/2003CA2477400A1 Treatment for asthma or allergies
09/12/2003CA2477392A1 Methods for treating diseases related to intraocular pressure
09/12/2003CA2477391A1 Method of treating osteoarthritis
09/12/2003CA2477387A1 Treatment of female sexual dysfunction
09/12/2003CA2477125A1 Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
09/12/2003CA2477124A1 Azaspiro compounds for the treatment of pain
09/12/2003CA2477119A1 Compounds that modulate the activity of ptp-1b and tc-ptp
09/12/2003CA2477003A1 Compounds and methods of treating cell proliferative diseases
09/12/2003CA2476744A1 Solid pharmaceutical compositions comprising lumiracoxib
09/12/2003CA2476724A1 Prevention of recurrence and metastasis of cancer
09/12/2003CA2476657A1 Haloacetamide and azide substituted compounds and methods of use thereof
09/12/2003CA2476651A1 Irreversible selective androgen receptor modulators and methods of use thereof
09/12/2003CA2476580A1 Thiazole and oxazole derivatives that modulate ppar activity
09/12/2003CA2476410A1 Methods to increase or decrease bone density
09/12/2003CA2476050A1 Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
09/12/2003CA2475690A1 Diagnostic method for glaucoma
09/12/2003CA2474811A1 Process for preparing 3-(2-(4-(6-fluorobenzo(d) isoxazol-3-yl)-piperidin-1yl)-ethyl)-2-methyl-6,7,8,9-tetrahydro-4h-pyrido-(1,2-a) pyrimidin-4-one
09/12/2003CA2455447A1 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
09/11/2003WO2003074511A1 Quinoline derivatives
09/11/2003WO2003074500A2 N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
09/11/2003WO2003074449A2 Multi-substitued selective androgen receptor modulators and methods of use thereof
09/11/2003WO2003074056A1 Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered orally
09/11/2003WO2003074054A1 Ophthalmic composition comprising ascomycin
09/11/2003WO2003074024A1 Formoterol superfine formulation
09/11/2003US20030171605 Reduced hypercalcemic activity and enhanced stability in vivo; used as substitutes for natural and synthetic vitamin D3 compounds.
09/11/2003US20030171596 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
09/11/2003US20030171591 Process for producing optically active sulfoxide derivative
09/11/2003US20030171590 Preparation of terfenadine carboxylate metabolite and carebastine derivatives with reduced side effects
09/11/2003US20030171587 Antimicrobial 2-pyridones, their compositions and uses
09/11/2003US20030171585 Anti-inflammatory compounds
09/11/2003US20030171584 6-Substituted pyrido-pyrimidines
09/11/2003US20030171579 N-benzyl-N'-phenylurea derivatives; inhibitors of the coagulation factors Xa and VIIa
09/11/2003US20030171577 Intermediates in cephalosporin production
09/11/2003US20030171573 Multivalently interactive molecular assembly, capturing agent, drug carrier, calcium chelating agent, and drug enhancer
09/11/2003US20030171556 Diagnosis and therapeutic treatment of Alzheimer's Disease; drug screening
09/11/2003US20030171552 A single-chain T-cell receptor covalently linked to single-chain antibody; anticarcinogenic agents for treating cancer
09/11/2003US20030171541 Selective binding agents, vectors, host cells, and methods for producing GPCR polypeptides; diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with GPCR polypeptides
09/11/2003US20030171496 Drug delivery compositions and medical devices containing block copolymer
09/11/2003US20030171441 Therapy for drug resistant virus
09/11/2003US20030171440 Tramadol analogs and uses thereof
09/11/2003US20030171439 Methods and compositions for nasal administration of Modafinil
09/11/2003US20030171438 Method for treatment of external secretion disorders
09/11/2003US20030171437 Pharmaceutical composition
09/11/2003US20030171436 Levothyroxine compositions having unique triiodothyronine Tmax properties
09/11/2003US20030171433 Mixture containing fatty acid; adjust fat concentration
09/11/2003US20030171432 Treating irrtable bowel syndrome or disease
1 ... 5345 5346 5347 5348 5349 5350 5351 5352 5353 5354 5355 5356 5357 5358 5359 5360 5361 5362 5363 5364 5365 ... 7860